Edgewise Therapeutics, Inc.(EWTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
EWTX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Edgewise Therapeutics, Inc. (EWTX), a Healthcare sector company. EWTX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Edgewise Therapeutics, Inc. reports net income of $-57.3M, free cash flow of $-42.5M. Top institutional holders of EWTX by reported 13-F value include ORBIMED ADVISORS, Paradigm Biocapital Advisors, RA CAPITAL MANAGEMENT, L.P., based on the most recent SEC filings. EWTX trades on the Nasdaq exchange and files with the SEC under CIK 1710072. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EWTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Edgewise Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-57.3M
Free Cash Flow
Q2 2026
$-42.5M
ROIC
Q2 2026
-55.3%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-25.4% YoYOperating Income
-20.5% YoYEPS (Diluted)
-12.4% YoYTotal Assets
+13.5% YoYOp. Cash Flow
-31.9% YoYFree Cash Flow
-30.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-167.8M -25.4% | $-133.8M -33.6% | $-100.2M -48.1% | $-67.6M -58.0% | $-42.8M -150.0% | $-17.1M |
| Operating Income | $-191.4M -20.5% | $-158.8M -38.9% | $-114.4M -59.6% | $-71.7M -65.8% | $-43.2M -151.4% | $-17.2M |
| EPS (Diluted) | $-1.63 -12.4% | $-1.45 +7.6% | $-1.57 -24.6% | $-1.26 -10.5% | $-1.14 +95.1% | $-23.17 |
| Total Assets | $552.6M +13.5% | $486.8M +43.2% | $340.0M -7.4% | $367.1M +28.7% | $285.2M +117.5% | $131.1M |
| Operating Cash Flow | $-143.8M -31.9% | $-109.0M -18.6% | $-91.9M -74.7% | $-52.6M -57.1% | $-33.5M -129.0% | $-14.6M |
| Free Cash Flow | $-144.1M -30.6% | $-110.3M -12.9% | $-97.7M -67.9% | $-58.2M -70.2% | $-34.2M -130.3% | $-14.8M |
Get alerted when EWTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Edgewise Therapeutics, Inc. including:
Top Institutional Holders of EWTX
ORBIMED ADVISORS LLC
$630.5M15,518,492 shParadigm Biocapital Advisors LP
$415.1M10,215,455 shRA CAPITAL MANAGEMENT, L.P.
$341.0M8,392,730 shBlackRock, Inc.
$268.4M6,606,336 shJupiter Topco LLC
$246.9M6,075,331 shFMR LLC
$223.0M5,489,135 shNovo Holdings A/S
$217.4M5,350,000 shDRIEHAUS CAPITAL MANAGEMENT LLC
$192.1M4,728,623 shPERCEPTIVE ADVISORS LLC
$177.7M4,373,974 shVANGUARD CAPITAL MANAGEMENT LLC
$156.9M3,860,670 sh
| Fund | Value | Shares |
|---|---|---|
| ORBIMED ADVISORS LLC | $630.5M | 15,518,492 |
| Paradigm Biocapital Advisors LP | $415.1M | 10,215,455 |
| RA CAPITAL MANAGEMENT, L.P. | $341.0M | 8,392,730 |
| BlackRock, Inc. | $268.4M | 6,606,336 |
| Jupiter Topco LLC | $246.9M | 6,075,331 |
| FMR LLC | $223.0M | 5,489,135 |
| Novo Holdings A/S | $217.4M | 5,350,000 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $192.1M | 4,728,623 |
| PERCEPTIVE ADVISORS LLC | $177.7M | 4,373,974 |
| VANGUARD CAPITAL MANAGEMENT LLC | $156.9M | 3,860,670 |
More Healthcare Companies
View all Healthcare →Put EWTX on your watchlist
Track score changes the day Edgewise Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is EWTX a good stock to buy?
13F Pro's AI-powered analysis of Edgewise Therapeutics, Inc. (EWTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EWTX are available on the EWTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. EWTX is classified as a mid company.
Which hedge funds own EWTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EWTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Edgewise Therapeutics, Inc.'s investment landscape.